Archive for the ‘Treatment’ Category

Dr. Steven Phillips on Chronic Inflammation

http://  Approx. 1 Hour

March 25, 2023

Dr. Steven Phillips Discusses Chronic Inflammation

Dr. Steven Phillips discusses chronic inflammation and its management, especially in the context of long COVID and “vaccine” injuries.

Dr. Steven Phillips’ bio: Steven Phillips, MD is a well published, Yale-trained physician, researcher, and bestselling author, whose focus of medical practice and research is that chronic and autoimmune illness can be caused by underlying infections.

Dr. Phillips’ substack: https://zerospin.substack.com/

Amazon.com: Chronic: The Hidden Cause of the Autoimmune Pandemic and How to Get Healthy Again (Audible Audio Edition): Steven Phillips MD, Dana Parish, Teri Schnaubelt, Thomas Allen, Brilliance Audio: Books https://www.amazon.com/Chronic-Hidden…

http://

Dr. Steven Phillips Discusses Chronic Diseases (Lyme & COVID)

Steven Phillips, M.D. is a renowned Yale-trained physician, author, international lecturer, and media go-to expert. Well-published in the medical literature, he has treated over 20,000 patients with complex, chronic illness from nearly 20 countries. Phillips experienced firsthand the nightmare of an undiagnosed, serious infection after nearly dying from his own “mystery illness,” and having to save his own life when 25 doctors could not.

Here are the questions we will ask Dr. Phillips:

  • What is Lyme+?
  • What is your own story of Lyme?
  • You say that many infections are categorized as Lyme, how do we separate them
  • Are there good tests for Lyme+?
  • Is it treatable?
  • Is there hope for hundreds of thousands of patients of Lyme+?
  • How can an infection cause autoimmune disorders?
  • What is the role of Th1 and Th2 system in this context?
  • Why does it become chronic?
  • Do I have a vector borne infection?
  • We are seeing the same issue with COVID – Is COVID becoming similarly mismanaged?
  • How should patients approach their chronic Lyme+?
  • Is there hope?
  • How do people get help from you?
  • Do you train other doctors with your protocol?
  • Do they reach out to you?
  • On page 63 you write: Despite my repeatedly negative brucellosis testing at U.S. labs, I shared with my Lyme doctor my ideas for an aggressive combination antibiotic treatment against this infection. Nothing else was working, so my doctor agreed to the plan, and by the second month of treatment I started to improve.
  • Tell us about Jarish-Hexheimer reaction
  • Before we go, tell us how can people find you?

For more:

Hospital payments include:

  • A “free” required PCR test in the Emergency Room or upon admission for every patient, with government-paid fee to hospital.  This test, like Lyme testing, is an utter farce.
  • Added bonus payment for each positive COVID-19 diagnosis, based on a worthless test.
  • Another bonus for a COVID-19 admission to the hospital, based on a worthless test.
  • A 20% “boost” bonus payment from Medicare on the entire hospital bill for use of remdesivir instead of medicines such as Ivermectin, all based on a worthless test.
  • Another and larger bonus payment to the hospital if a COVID-19 patient is mechanically ventilated, all based on a worthless test.
  • More money to the hospital if cause of death is listed as COVID-19, even if patient did not die directly of COVID-19, which is all based on a worthless test.
  • A COVID-19 diagnosis also provides extra payments to coroners, all based on a worthless test.

CMS implemented “value-based” payment programs that track data such as how many workers at a healthcare facility receive a COVID-19 “vaccine.” Now we see why many hospitals implemented COVID-19 vaccine mandates. They are paid more.  Source

For those paying attention, COVID is a replay of Lyme and many of the same tactics have been deployed.

Category:

Activism, Inflammation, Lyme, Treatment, Viruses

IV Antibiotics Helpful For PTLDS

https://danielcameronmd.com/intravenous-antibiotics-helpful-for-ptlds/

INTRAVENOUS ANTIBIOTICS HELPFUL FOR PTLDS

antibiotics-ptlds

Post Treatment Lyme Disease Syndrome (PTLDS) can develop in patients even after receiving antibiotic treatment for Lyme disease. Although the exact cause of PTLDS is unknown, it could be due to a persistent infection. PTLDS is characterized by fatigue, pain and cognitive difficulties.

By 

In their study “Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis,” Zhang and colleagues described a meta-analysis review of four Randomized Clinical Trials (RCT) addressing Post-Treatment Lyme Disease Syndrome.¹

The four randomized controlled trials included 485 subjects who met the following inclusion criteria:

  • Randomized controlled trials
  • Patients with Post-Lyme Disease Syndrome which has persisted for at least 6 months after treatment of the initial infection and who tested positive by IgG Western blot
  • Patients aged 18 years and above
  • Number of cases providing valid data to measure outcomes
  • Studies that the control group used placebo, while the observation group took the antibiotic

Their meta-analysis showed that ceftriaxone had better results than placebo on FSS. “FSS-11 is the most widely used scale to measure the fatigue severity of the subjects,” wrote Zhang et al.

“Ceftriaxone treatment may be the best choice for antibiotic treatment of PTLD, which provides useful guidance for antibiotic treatment of PTLD in the future.”

The systemic meta-analysis concluded that intravenous ceftriaxone may be the best choice for treating Post-Treatment Lyme Disease Syndrome.

An NIH-sponsored clinical trial demonstrated that intravenous ceftriaxone therapy improved patients’ cognitive function in the short term, according to Fallon.² There were no trials addressing pain.

The authors were not able to show significant gains in the Beck Depression Inventory (BDI), Mental Health Scale and Physical Functioning Scales. Neither were they able to show significant gains with oral doxycycline.

Zhang et al. acknowledged several limitations to their study. “The number of RCTs is small; The duration and dose of treatment in these RCTs are not uniform; The follow-up time of various RCTs is different to some extent.”

Author’s Note: I have been reluctant to recognize the term PTLDS until there is a reliable test to exclude a persistent infection. This systemic meta-analysis validated my concerns that PTLDS may be the result of a persistent infection.

Related Articles:

Podcast: Post-Treatment Lyme Disease Syndrome Cases

4 Distinct Post-Treatment Lyme Disease Syndromes?

Number of Post-Treatment Lyme Disease Syndrome cases expected to soar

References:
  1. Zhang X, Jiang Y, Chen Y, et al. Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis. BMC Infect Dis. Jan 12 2023;23(1):22. doi:10.1186/s12879-023-07989-4
  2. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. Mar 25 2008;70(13):992-1003. doi:10.1212/01.WNL.0000284604.61160.2d

________________

For more:

Please note that the FDA’s continued attack on supplements and medications it deems a threat could very well impact Lyme/MSIDS patients.

Category:

Activism, Lyme, research, Treatment

Magic Mushrooms for Lyme: A Case Study

https://www.dovepress.com/the-effectiveness-of-microdosed-psilocybin-in-the-treatment-of-neurops-peer-reviewed-fulltext-article-IMCRJ

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

Authors Kinderlehrer DA

Published 3 March 2023 Volume 2023:16 Pages 109—115

DOI https://doi.org/10.2147/IMCRJ.S395342

Review by Single anonymous peer review

Download Article [PDF]

Daniel A Kinderlehrer
Private Practice, Denver, CO, USA

Correspondence: Daniel A Kinderlehrer, Email kinderlehrer@gmail.com

Abstract: Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease is associated with autoimmune induced neuroinflammation. This case report describes an immunocompetent male with serologically positive neuropsychiatric Lyme disease who did not tolerate antimicrobial or psychotropic medications and whose symptoms remitted when he began psilocybin in microdosed (sub-hallucinogenic) amounts. A literature review of its therapeutic benefits reveals that psilocybin is both serotonergic (affecting serotonin) and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation. The role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.

For more:

Category:

Lyme, research, Treatment

Lawsuit Against the FDA for Their Illegal Anti-Ivermectin Actions

https://pierrekory.substack.com/p/the-case-against-the-fda-for-their

The Case Against The FDA For Their Illegal Anti-Ivermectin Actions

The case brought by Drs. Paul Marik, Mary Bowden, and Robert Apter is now at the Court of Appeals. I was interviewed for this awesome Federalist article today where I landed some powerful blows.

Pierre Kory, MD, MPA
Feb. 21, 2023

I am very happy about the coverage our case received today in the below Federalist article which can also be found here. I say “our” case because not only does it affect everyone, but also because the FLCCC, the Association of American Physicians and Surgeons, and America’s Front-Line Doctors all submitted amicus briefs in support of the plaintiffs. The journalist totally understood how dangerous it is to concentrate so much power in a single Federal government agency (as well as the Federal government in general). The article was published under the Medical Ethics section of the paper and like I said, I am pretty proud of the quotes she decided to include. I think I will read it again I enjoyed it so much! Here it is:

MEDICAL ETHICS

( See link for article)

_________________

For more on ivermectin:

Category:

Activism, Treatment, Viruses

Reversible Dementia Caused By Lyme: Case Study

https://www.globallymealliance.org/news/2023-case-study-reversible-dementia-caused-by-lyme-disease

2023 Case Study: Reversible Dementia Caused by Lyme Disease

by Admin at Global Lyme Alliance on February 27, 2023

<span id="hs_cos_wrapper_name" class="hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_text" style="" data-hs-cos-general-type="meta_field" data-hs-cos-type="text" >2023 Case Study: Reversible Dementia Caused by Lyme Disease</span>
A case of reversible dementia with Lyme treatment?

Annals of Geriatric Medicine and Research (Sanchini, C., et al.) 2.6.23, published “A case of reversible dementia? Dementia vs delirium in Lyme disease.” The report describes a case of a 75-year-old man who was admitted to the Alzheimer’s Disease Care Unit of the Institute Golgi in Abbiategrasso, Italy.

According to the case report, the man had been recently discharged from a local hospital with a diagnosis of “cognitive impairment, deficit of memory, and poor capacity of criticism compatible with degenerative disease.”

The patient was a multilingual interpreter with a high school degree. He enjoyed walking in the countryside with his dog, but he had been experiencing knee pain – for about a month. The pain would worsen and migrate to his other joints. The case also reports that he had been showing minor memory deficiency and ideomotor slowdown.

A CT scan showed abnormalities, but blood tests were within normal ranges, the only thing noted was increased inflammation. As time went on, the patient became more confused and disoriented, presenting with hallucinations, aggressive behavior, and insomnia.

With the patient having arthritis, he was tested for Lyme. Lyme antibodies were detected by the western blot. Initial intravenous ceftriaxone treatments did not alleviate the patient’s symptoms. Oral doxycycline was administered as well as a brief course of quetiapine to manage the hallucinations.

Soon after 6–7 days of antibiotic therapy, delusional symptoms and hallucinations were reduced, and his insomnia improved. Urinary incontinence completely resolved. His behavioral profile also improved, with a reduction in agitation, aggression, and depression. His language became more fluent and communicative.

Read the full case study here.

_______________

**Comment**

This proves that antimicrobial therapy helps Lyme/MSIDS patients, unfortunately, this patient will most probably suffer relapses as this duration of therapy has been proven to be insufficient time and time again.  Herein lies one of the most glaring problems that has not changed in 40 years.  The other glaring problem is the coinfection involvement that often occurs, necessitating different medications.

But, the band plays on…..

For more:

How many more dementia/Alzheimer’s patients have undiagnosed tick-borne illness?

Category:

Alzheimer's, Lyme, research, Treatment